After 12 months, treatment outcomes showed 1.8% clinical failure, 6.8% immunological failure, 17.9% virological failure, 117/129 (90.6%) patients continued treatment, 8 patients give up therapy, 4 deaths, 2 patients with anemia due to AZT, 1 patient with blood creatinine increased, no new cases of diabetes.